ThermoGenesis (THMO)
(Delayed Data from OTC)
$0.15 USD
+0.02 (16.23%)
Updated Jul 12, 2024 03:15 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
THMO 0.15 +0.02(16.23%)
Will THMO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for THMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for THMO
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
THMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
Other News for THMO
ThermoGenesis Board Shake-Up Amid Governance Concerns
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Nasdaq Jumps 300 Points; Oracle Shares Spike Higher